Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
Cancer Biology & Therapy|April 15, 2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinomaMaria R Abbattista, Stephen M F Jamieson, Yongchuan Gu, et al.
Molecular Pharmacology|October 11, 2011
Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxiaChristopher P Guise, Maria R Abbattista, Smitha R Tipparaju, et al.
International Journal of Molecular Sciences|June 27, 2024
Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623Abigail V Sharrock, Jeff S Mumm, Elsie M Williams, et al.
Cancers|July 2, 2016
Advancing Clostridia to Clinical Trial: Past Lessons and Recent ProgressAlexandra M Mowday, Christopher P Guise, David F Ackerley, et al.
International Journal of Radiation Oncology, Biology, Physics|April 27, 2005
Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cellsNaomi Chadderton, Rachel L Cowen, Freda C D Sheppard, et al.
Molecular Cancer Therapeutics|October 8, 2009
Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylatorsWilliam R Wilson, Stephen M Stribbling, Frederik B Pruijn, et al.
Bioorganic & Medicinal Chemistry|January 18, 2014
Synthesis and cytotoxicity of pyranonaphthoquinone natural product analogues under bioreductive conditionsAmanda M Heapy, Adam V Patterson, Jeff B Smaill, et al.
Journal of Medicinal Chemistry|December 28, 2002
Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamineMichael P Hay, Swarna A Gamage, Mary S Kovacs, et al.
Pageof 9